The market does not need much of an excuse to punish a stock, and yesterday GlaxoSmithKline gave it just that. The British drugmaker announced that the final trials of a new asthma medication showed that the drug, Relovair, is no better than Advair (also known as Seretide), a similar GSK medication already on the market. Relovair’s main advantage is that patients need only take it once a day, as opposed to Advair’s twice-a-day dose.
市场不需要太多借口来惩罚一只股票，而葛兰素史克(GlaxoSmithKline, GSK)周一提供了充足理由。这家英国制药商宣布，最新哮喘药物Relovair的最终试验表明，新药效果并未超越GSK目前销售的哮喘药Advair——又名舒利迭(Seretide)。Relovair的主要优点是患者只需每天服药一次，而Advair的剂量是一天两次。
您已阅读25%（607字），剩余75%（1836字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。